Same Indication

Ipilimumab vs Mirabegron

Ipilimumab vs Mirabegron: Overview

This comparison examines the pharmacological differences between Ipilimumab and Mirabegron.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Ipilimumab β€” 14.7 days.

Chemical Properties

Type: Ipilimumab β€” Antibody; Mirabegron β€” Small molecule.